iPSpine
induced Pluripotent stem sell-based therapy for Spinal regeneration
Duration
January 2019 - June 2024Project Manager
iPSpine seeks to offer novel technologies and Advanced Therapy Medicinal Products (ATMPs) for the advanced therapy research and development community.
Intervertebral disc degeneration (IDD) will be the showcase, offering improved quality of life for millions of patients with IDD-induced Low Back Pain (LBP), through long-lasting reduction of LBP, reduced LBP-related
premature retirement, and improved socio-economic contribution.
With their multi-disciplinary expertise in the development of advanced therapies and their translation from bench to bedside, the aim of the iPSpine team is to investigate and develop a new advanced therapy medicinal product (ATMP) of the future, based on a novel developmental biology-based therapeutic strategy employing pluripotent stem cells (iPSC) and smart biomaterials.
The iPSpine consortium will develop and demonstrate Proof-of-concept with the aid of novel and extended knowledge, tools and technology platforms. Hereby, iPSpine has the ambition to make a significant contribution by reducing translational bottlenecks through open innovation and take European leadership in the development of ATMPs.
Collaborative Partners
-
Eindhoven University of Technology
-
Utrecht University
-
Université de Nantes
-
Universitair Medisch Centrum Utrecht
-
National University of Ireland
-
Universitaet Bern Switzerland
-
Institut National de la Santé et de la Recherche Médicale
-
Naturwissenschaftliches Und Medizinisches Institut An Der Universitaet Tuebingen De
-
Ao-Forschungsinstitut Davos Switzerland
-
Sheffield Hallam University United Kingdom
-
Universita Campus Bio-Medico di Roma
-
Ntrans Technologies Bv Netherlands
-
Université de Montpellier
-
University of Miami
-
Spineserv Gmbh & Co. Kg Germany
-
Hong Kong University of Science and Technology
-
Pharmalex Gmbh Germany
-
Catalyze B.V. Netherlands
-
Stichting Nationaal Reumafonds
-
University of Ulm
